Introduction: For over 60 years vitamin K antagonists have been the mainstay of oral therapy
for treatment and prevention of venous and arterial thromboembolic disease. The …

The recently introduced oral anticoagulants, dabigatran, rivaroxaban and apixaban, were
shown, in randomized controlled trials, to be at least as effective and safe as monitored …

Introduction: Venous thromboembolism is a major global health burden. Since the 1930s,
prevention of stroke and pulmonary embolism in these patients has been achieved using …

Venous thromboembolism is commonly defined as a situation in which blood clot forms in
blood vessels. It has two types Deep vein thrombosis (clot became in leg, groin or arm) and …

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary
embolism, is a common and potentially preventable cause of morbidity and mortality …

Introduction Betrixaban is a novel direct oral factor Xa inhibitor approved by the Food and
Drug Administration for prophylaxis of venous thromboembolism in adult patients …

Approximately 900,000 people are affected by some sort of venous thromboembolic (VTE)
event every year in the United States. VTE diagnosis used to mean treatment with …

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the factor
Xa (FXa) inhibitor betrixaban for extended-duration prophylaxis of acute medically ill …

Following the clinical approval of novel oral anticoagulants as alternatives to the vitamin K
antagonists, many additional novel oral anticoagulant drugs are currently in early and …

Purpose The role of betrixaban in the prevention of venous thromboembolism (VTE) in
acutely medically ill patients and its efficacy and safety profiles are reviewed. Summary …